Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the Company has partnered with Watson Pharma, Inc., a subsidiary of Watson Pharmaceuticals, Inc. (NYSE: WPI) to introduce tizanidine hydrochloride capsules, an authorized generic version of ZANAFLEX CAPSULES® (tizanidine hydrochloride).
Tizanidine hydrochloride capsules is a short-acting drug indicated for the management of spasticity. Because of the short duration of effect, treatment with tizanidine hydrochloride capsules should be reserved for those daily activities and times when relief of spasticity is most important.
Acorda will receive a royalty from Watson based on product sales.
Natural compounds show promise in modulating heme breakdown, offering new therapeutic avenues